Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr Reddy’s Laboratories has secured a major regulatory milestone with the European Commission granting marketing authorisation for AVT03, its biosimilar to denosumab used in osteoporosis treatment. The approval covers all EU member states as well as Iceland, Liechtenstein and Norway under the European Economic Area framework.The company said AVT03 is a biosimilar version of Prolia…